Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated...
22 insider purchases on record · latest filing 2024-05-22.
Insiders have also filed 4 sale transactions at ERAS.